H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kamada today and set a price target of $11.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Fein has given his Buy rating due to a combination of factors that highlight Kamada’s strong financial performance and strategic growth initiatives. Kamada reported a significant increase in revenue and adjusted EBITDA for the first half of 2025, driven by robust sales of Glassia and Varizig, as well as royalty payments. This growth reflects the company’s successful expansion in ex-US markets and increased demand for its products in the US.
Furthermore, Kamada’s diverse portfolio and strategic initiatives, such as their four-pillar growth strategy, are expected to drive future growth. This strategy includes organic commercial growth, business development, and M&A transactions, as well as advancements in their plasma collection operations and the pivotal Phase 3 inhaled AAT program. The ongoing post-marketing research for Cytogam is anticipated to generate data that could expand its utilization, further supporting Kamada’s growth prospects.
Fein covers the Healthcare sector, focusing on stocks such as Biogen, Amylyx Pharmaceuticals Inc, and Kymera Therapeutics. According to TipRanks, Fein has an average return of 9.5% and a 46.76% success rate on recommended stocks.
In another report released today, Benchmark Co. also maintained a Buy rating on the stock with a $15.00 price target.